PP
NVO

PagnatoKarp Partners’s Novo Nordisk NVO Stock Holding History

PagnatoKarp Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-7,284
Closed -$222K – 98
2020
Q1 		$222K Buy
7,284
+384
+6% +$11.4K 0.06% 147
2019
Q4 		$200K Buy
+6,900
New +$191K 0.03% 178

Other funds holding NVO

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return

PagnatoKarp Partners's NVO Position: Q2 2020 in Review

PagnatoKarp Partners sold out of Novo Nordisk (NVO) in Q2 2020, closing a stake of 7,284 shares — an estimated $222K sold.

PagnatoKarp Partners first reported a position in NVO in Q4 2019 and held it in 2 quarters. The position peaked at $222K in Q1 2020. 661 funds tracked by Wall St. Rank hold NVO as of Q2 2020.

  • PagnatoKarp Partners reported no remaining Novo Nordisk position as of Q2 2020 after selling out during the quarter.
  • PagnatoKarp Partners sold 7,284 Novo Nordisk shares in Q2 2020, an estimated $222K.
  • PagnatoKarp Partners first reported a position in Novo Nordisk in Q4 2019 and held it in 2 quarters.
  • PagnatoKarp Partners's Novo Nordisk position peaked at $222K in Q1 2020.
  • 661 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2020.

Based on PagnatoKarp Partners's 13F filing for Q2 2020.